Table 1. Main characteristics of the included studies.
| Study | Country | Tumor type | Case number (LSA/HSA) | Age (years) | Sex (M/F) | Neoadjuvant chemotherapy (LSA/HSA) | Surgical treatment | Follow-up (months) | Survival analysis | Cut-off value |
|---|---|---|---|---|---|---|---|---|---|---|
| Caras et al. (2017) [23] | U.S.A. | BC and UTUC | 1292/4282 | 65 | 4228/1340 | NA | RC or TURBT | 1 | NA | 3.5 g/dl |
| Chan et al. (2013) [35] | China | BC | 62/55 | 68 ± 10 | 99/18 | NA | RC | 31 ± 29 | CSS, OCS, OS | 3.9 g/l |
| Cho et al. (2014) [30] | Korea | UTUC | 35/112 | 70 | 40/106 | NA | RNU | 33 | RFS | 3.5 g/dl |
| Cui et al. (2017) [24] | China | UTUC | 54/36 | 65.66 | 107/62 | NA | RNU | 53.7 | OS, CSS | 4.37 g/l |
| Djaladat et al. (2014) [28] | U.S.A. | BC | 197/1274 | 67 | 1154/317 | 15/92 | RC | 148.8 | OS, RFS | 3.5 g/dl |
| Fujita et al. (2015) [36] | Japan | UTUC | NA | 70 | 221/85 | NA | RNU | 41 | RFS, CSS | NA |
| Garg et al. (2014) [37] | U.S.A. | BC | 150/947 | 68 | 831/266 | 19/109 | RC | 25.2 | NA | 4.0 g/dl |
| Hinata et al. (2015) [31] | Japan | BC | NA | 68.6 | 575/155 | NA | RC | 52 | OS, RFS | 3.5 g/l |
| Huang et al. (2017) [25] | China | UTUC | 17/408 | 67 | 279/146 | NA | RUN | 38.5 | OS, CSS | 3.5 g/l |
| Johnson et al. (2015) [38] | U.S.A. | BC | 102/587 | 73 | 530/159 | NA | RC | 1 | NA | 3.5 g/dl |
| Kluth et al. (2014) [39] | U.S.A. | UTUC | NA | 70 | 175/67 | NA | RNU | 9 | CSS | 3.7 g/dl |
| Krane et al. (2013) [29] | U.S.A. | BC | NA | 67.4 | 55/13 | NA | RC | 25 | OS, CSS | 3.5 g/dl |
| Ku et al. (2015) [40] | Korea | BC | NA | 65.1 | 362 /57 | NA | RC | 37.7 | OS, CSS | 3.5 g/dl |
| Lambert et al. (2013) [41] | Britain | BC | 31/156 | 67.4 | 153/34 | 29/6 | RC | 26.2 | OS, CSS | 3.5 g/dl |
| Laurent et al. (2017) [26] | France | BC | 95/98 | 75.2 | 164/29 | NA | RC | 9.1 | OS | 3.5 g/dl |
| Lavallee et al. (2014) [42] | Canada | BC | 341/1090 | 70 | 1819/484 | NA | RC | NA | NA | 3.7 g/dl |
| Liu et al. (2016) [43] | China | BC | 129/167 | 61.71 | 250/45 | NA | RC | 72 | RFS, CSS | 4.0 g/dl |
| Morgan et al. (2011) [44] | U.S.A. | BC | 30/139 | 78.8 | 122/47 | NA | RC | 3 | NA | 3.7 g/dl |
| Mursi et al. (2013) [45] | Egypt | BC | 24/7 | 58.4 | 22/9 | NA | RC | 3 | NA | 3.5 g/dl |
| Nakagawa et al. (2017) [27] | Japan | BC | NA | 69 | 248/58 | NA | RC | 6.8 | OS | 3.5 g/dl |
| Sharma et al. (2016) [46] | U.S.A. | BC | NA | 70.1 | 209/65 | NA | RC | NA | NA | 4.0 g/dl |
| Sheth et al. (2016) [47] | U.S.A. | UTUC | NA | 71 | 77/24 | NA | RNU or partial ureterectomy | 18.5 | RFS, OS | 4.0 g/dl |
| Taguchi et al. (2016) [48] | Japan | UC | NA | 68 | 160/40 | NA | RNU and RC | 12 | OS | 3.5 g/dl |
Abbreviations: HSA, high serum albumin; LSA, low serum albumin; NA, not available; TURBT, transurethral resection of bladder tumor.